应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01530 三生制药
休市中 04-19 16:08:35
5.560
-0.100
-1.77%
最高
5.620
最低
5.500
成交量
1,075万
今开
5.610
昨收
5.660
日振幅
2.12%
总市值
135.60亿
流通市值
135.60亿
总股本
24.39亿
成交额
5,983万
换手率
0.44%
流通股本
24.39亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
三生制药(01530)4月16日斥资约2031.52万港元回购353.7万股
智通财经 · 04-16
三生制药(01530)4月16日斥资约2031.52万港元回购353.7万股
三生制药盘中异动 大幅下跌5.10%报5.580港元
自选股智能写手 · 04-16
三生制药盘中异动 大幅下跌5.10%报5.580港元
三生制药(01530)4月15日斥资约1559.84万港元回购264.95万股
智通财经网 · 04-15
三生制药(01530)4月15日斥资约1559.84万港元回购264.95万股
三生制药(01530.HK)4月15日耗资1559.8万港元回购264.95万股
格隆汇资讯 · 04-15
三生制药(01530.HK)4月15日耗资1559.8万港元回购264.95万股
三生制药04月15日遭主力抛售666万元 环比增加142.18%
自选股智能写手 · 04-15
三生制药04月15日遭主力抛售666万元 环比增加142.18%
三生制药(01530.HK)回购174.6万股 涉资约1038.88万港元
金融界 · 04-15
三生制药(01530.HK)回购174.6万股 涉资约1038.88万港元
三生制药(01530.HK)特比澳新适应症申请获批
阿斯达克财经 · 04-14
三生制药(01530.HK)特比澳新适应症申请获批
三生制药(01530):重组人血小板生成素注射液(特比澳®)儿童ITP适应症获批
智通财经网 · 04-12
三生制药(01530):重组人血小板生成素注射液(特比澳®)儿童ITP适应症获批
三生制药4月12日斥资1038.88万港元回购174.6万股
新浪港股 · 04-12
三生制药4月12日斥资1038.88万港元回购174.6万股
三生制药(01530.HK)4月12日耗资1039万港元回购174.6万股
港股那点事 · 04-12
三生制药(01530.HK)4月12日耗资1039万港元回购174.6万股
三生制药(01530)4月12日斥资1038.88万港元回购174.6万股
智通财经 · 04-12
三生制药(01530)4月12日斥资1038.88万港元回购174.6万股
三生制药4月11日获南向资金加仓544.70万股
自选股智能写手 · 04-12
三生制药4月11日获南向资金加仓544.70万股
【券商聚焦】东北证券维持三生制药(01530)“买入”评级 指公司产品体系成熟 看好长远发展
金吾财讯 · 04-11
【券商聚焦】东北证券维持三生制药(01530)“买入”评级 指公司产品体系成熟 看好长远发展
三生制药斥资661.34万港元回购108.15万股股票
和讯网 · 04-11
三生制药斥资661.34万港元回购108.15万股股票
三生制药4月10日斥资661.34万港元回购108.15万股
新浪港股 · 04-11
三生制药4月10日斥资661.34万港元回购108.15万股
三生制药(01530)4月10日斥资661.34万港元回购108.15万股
智通财经网 · 04-10
三生制药(01530)4月10日斥资661.34万港元回购108.15万股
三生制药04月09日遭主力抛售816万元 环比增加348.35%
自选股智能写手 · 04-09
三生制药04月09日遭主力抛售816万元 环比增加348.35%
三生制药(01530)4月8日斥资431.34万港元回购72.15万股
智通财经网 · 04-08
三生制药(01530)4月8日斥资431.34万港元回购72.15万股
三生制药04月08日遭主力抛售182万元 环比增加193.55%
自选股智能写手 · 04-08
三生制药04月08日遭主力抛售182万元 环比增加193.55%
《大行报告》大摩降三生制药(01530.HK)目标价至7.5元 评级“与大市同步”
阿斯达克财经 · 04-08
《大行报告》大摩降三生制药(01530.HK)目标价至7.5元 评级“与大市同步”
加载更多
公司概况
公司名称:
三生制药
所属市场:
SEHK
上市日期:
--
主营业务:
三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。
发行价格:
--
{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":5.56,"timestamp":1713514115029,"preClose":5.66,"halted":0,"volume":10754369,"delay":0,"floatShares":2438920412,"shares":2438920412,"eps":0.6859668,"marketStatus":"休市中","marketStatusCode":7,"change":-0.1,"latestTime":"04-19 16:08:35","open":5.61,"high":5.62,"low":5.5,"amount":59834524,"amplitude":0.021201,"askPrice":5.56,"askSize":679500,"bidPrice":5.55,"bidSize":157000,"shortable":3,"etf":0,"ttmEps":0.674409779124769,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":5.66,"dividendRate":0.044081,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.8561318855845006,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2427846400","title":"三生制药(01530)4月16日斥资约2031.52万港元回购353.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427846400","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427846400?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:49","pubTimestamp":1713260952,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,该公司于2024年4月16日斥资约2031.52万港元回购353.7万股,回购价为每股5.58港元-5.84港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103348.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427818131","title":"三生制药盘中异动 大幅下跌5.10%报5.580港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427818131","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427818131?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:16","pubTimestamp":1713248178,"startTime":"0","endTime":"0","summary":"2024年04月16日下午盘14时16分,三生制药股票出现异动,股价大幅跳水5.10%。截至发稿,该股报5.580港元/股,成交量1081.55万股,换手率0.44%,振幅5.61%。资金方面,该股资金流入2012.51万港元,流出3622.35万港元。三生制药股票所在的药品行业中,整体跌幅为0.29%。其相关个股中,联康生物科技集团、中智药业、中生联合涨幅较大,振幅较大的相关个股有君圣泰医药-B、中生联合、三爱健康集团,振幅分别为17.60%、15.45%、13.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041614161887e80dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041614161887e80dd5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427641078","title":"三生制药(01530)4月15日斥资约1559.84万港元回购264.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427641078","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427641078?lang=zh_cn&edition=full","pubTime":"2024-04-15 18:19","pubTimestamp":1713176392,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,该公司于2024年4月15日斥资约1559.84万港元回购264.95万股,回购价为每股5.83港元-5.93港元。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102651.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427307874","title":"三生制药(01530.HK)4月15日耗资1559.8万港元回购264.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427307874","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2427307874?lang=zh_cn&edition=full","pubTime":"2024-04-15 18:19","pubTimestamp":1713176376,"startTime":"0","endTime":"0","summary":"格隆汇4月15日丨三生制药(01530.HK)公告,4月15日耗资1559.8万港元回购264.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151819398b25991c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151819398b25991c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427256010","title":"三生制药04月15日遭主力抛售666万元 环比增加142.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427256010","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427256010?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:16","pubTimestamp":1713168999,"startTime":"0","endTime":"0","summary":"04月15日, 三生制药股价跌1.18%,报收5.88元,成交金额5595万元,换手率0.39%,振幅2.52%,量比0.77。三生制药今日主力资金净流出666万元,连续7日净流出,上一交易日主力净流出275万元,今日环比增加142.18%。近一年数据显示,该股主力连续7日净流出后,次日下跌概率为40.00%,平均跌幅为2.42%。该股近5个交易日下跌2.80%,主力资金累计净流出2339万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出5672万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161707877e8f49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161707877e8f49&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427016704","title":"三生制药(01530.HK)回购174.6万股 涉资约1038.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427016704","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427016704?lang=zh_cn&edition=full","pubTime":"2024-04-15 10:39","pubTimestamp":1713148791,"startTime":"0","endTime":"0","summary":"三生制药 (01530.HK)公布,于2024年04月12日回购174.6万股,每股回购价介乎5.93港元至5.98港元,涉资约1038.88万港元。本年内至今为止(自普通决议案通过以来)累计购回证券数目为1011.4万股,占于普通决议案通过时已发行股份数目的0.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415105034877d4252&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415105034877d4252&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427397340","title":"三生制药(01530.HK)特比澳新适应症申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2427397340","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2427397340?lang=zh_cn&edition=full","pubTime":"2024-04-14 19:44","pubTimestamp":1713095040,"startTime":"0","endTime":"0","summary":"三生制药(01530.HK) 公布,公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准,用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液,此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应 症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342055/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783769","title":"三生制药(01530):重组人血小板生成素注射液(特比澳®)儿童ITP适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783769","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426783769?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:35","pubTimestamp":1712921752,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药 发布公告,公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已于4月2日获得批准,用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是由三生制药自主研制的重组人血小板生成素注射液,此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应症。目前,重组人血小板生成素注射液是中国ITP指南推荐首选的二线治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101950.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426041012","title":"三生制药4月12日斥资1038.88万港元回购174.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426041012","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2426041012?lang=zh_cn&edition=full","pubTime":"2024-04-12 18:14","pubTimestamp":1712916843,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年4月12日,该公司斥资1038.88万港元回购174.6万股,每股回购价为5.93-5.98港元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-12/doc-inarqpnt0138704.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-12/doc-inarqpnt0138704.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426069062","title":"三生制药(01530.HK)4月12日耗资1039万港元回购174.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426069062","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2426069062?lang=zh_cn&edition=full","pubTime":"2024-04-12 17:27","pubTimestamp":1712914067,"startTime":"0","endTime":"0","summary":"格隆汇4月12日丨三生制药(01530.HK)发布公告,2024年4月12日耗资1039万港元回购174.6万股,回购价格每股5.93-5.98港元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-12/doc-inarqies7964794.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-12/doc-inarqies7964794.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426206311","title":"三生制药(01530)4月12日斥资1038.88万港元回购174.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426206311","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426206311?lang=zh_cn&edition=full","pubTime":"2024-04-12 17:24","pubTimestamp":1712913846,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,于2024年4月12日,该公司斥资1038.88万港元回购174.6万股,每股回购价为5.93-5.98港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101752.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426524160","title":"三生制药4月11日获南向资金加仓544.70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426524160","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426524160?lang=zh_cn&edition=full","pubTime":"2024-04-12 09:31","pubTimestamp":1712885469,"startTime":"0","endTime":"0","summary":"4月11日, 南向资金增持三生制药544.70万股。截止当日收盘,港股通共持有三生制药73782.56万股,占流通股30.25%。三生制药近5个交易日下跌0.66%,港股通累计增持2349.45万股;近20个交易日上涨19.60%,港股通累计增持9246.11万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412094214876b774e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412094214876b774e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426817281","title":"【券商聚焦】东北证券维持三生制药(01530)“买入”评级 指公司产品体系成熟 看好长远发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2426817281","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2426817281?lang=zh_cn&edition=full","pubTime":"2024-04-11 15:21","pubTimestamp":1712820116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东北证券发研报指,近日,三生制药 发布2023年年度业绩公告。该行指,公司管线拥有29项在研产品管线,覆盖肿瘤科、肾科、自身免疫性疾病、皮肤科及眼科等多种治疗领域。其中 5个于2023年获批上市/通过一致性评价,12个处于临床III期/NDA阶段。该行续指,公司布局肿瘤、肾科等多个优势领域,产品体系成熟。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934891","is_publish_highlight":false,"gpt_icon":0},{"id":"2426765754","title":"三生制药斥资661.34万港元回购108.15万股股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2426765754","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2426765754?lang=zh_cn&edition=full","pubTime":"2024-04-11 08:53","pubTimestamp":1712796795,"startTime":"0","endTime":"0","summary":"快讯正文三生制药投资661.34万港元回购股份三生制药公司于2024年4月10日展开股份回购行动,涉及金额达661.34万港元,回购股份数量为108.15万股。此次回购的每股价格区间在6.03至6.19港元之间。和讯自选股写手风险提示:以上内容仅作为作者或者嘉宾的观点,不代表和讯的任何立场,不构成与和讯相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性,对此和讯不做任何保证和承诺。下载和讯APP查看快讯,体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110905498b0d404b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110905498b0d404b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426418478","title":"三生制药4月10日斥资661.34万港元回购108.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426418478","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2426418478?lang=zh_cn&edition=full","pubTime":"2024-04-11 08:21","pubTimestamp":1712794905,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年4月10日该公司斥资661.34万港元回购108.15万股股份,每股回购价格为6.03-6.19港元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-11/doc-inarmhzw4487983.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-11/doc-inarmhzw4487983.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426614404","title":"三生制药(01530)4月10日斥资661.34万港元回购108.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426614404","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426614404?lang=zh_cn&edition=full","pubTime":"2024-04-10 19:18","pubTimestamp":1712747935,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年4月10日该公司斥资661.34万港元...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100747.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426885159","title":"三生制药04月09日遭主力抛售816万元 环比增加348.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426885159","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426885159?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:16","pubTimestamp":1712650586,"startTime":"0","endTime":"0","summary":"04月09日, 三生制药股价涨3.29%,报收6.27元,成交金额8657万元,换手率0.57%,振幅5.93%,量比1.16。三生制药今日主力资金净流出816万元,连续3日净流出,上一交易日主力净流出182万元,今日环比增加348.35%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为53.33%,平均跌幅为1.92%。该股近5个交易日上涨4.68%,主力资金累计净流出1174万元;近20日主力资金累计净流出2436万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091617088758d561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091617088758d561&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425961024","title":"三生制药(01530)4月8日斥资431.34万港元回购72.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425961024","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2425961024?lang=zh_cn&edition=full","pubTime":"2024-04-08 18:37","pubTimestamp":1712572641,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年4月8日,该公司斥资431.34万港元...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_44.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_44.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099490.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425951017","title":"三生制药04月08日遭主力抛售182万元 环比增加193.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425951017","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425951017?lang=zh_cn&edition=full","pubTime":"2024-04-08 16:16","pubTimestamp":1712564218,"startTime":"0","endTime":"0","summary":"04月08日, 三生制药股价涨0.50%,报收6.07元,成交金额5909万元,换手率0.40%,振幅2.98%,量比0.77。三生制药今日主力资金净流出182万元,上一交易日主力净流出62万元,今日环比增加193.55%。该股近5个交易日上涨5.57%,主力资金累计净流出573万元;近20日主力资金累计净流出1919万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081617318afdc9f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081617318afdc9f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425818019","title":"《大行报告》大摩降三生制药(01530.HK)目标价至7.5元 评级“与大市同步”","url":"https://stock-news.laohu8.com/highlight/detail?id=2425818019","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425818019?lang=zh_cn&edition=full","pubTime":"2024-04-08 11:17","pubTimestamp":1712546220,"startTime":"0","endTime":"0","summary":"摩根士丹利发表研究报告指,三生制药(01530.HK) 是哺乳动物细胞表达体系下生物制药领域的龙头企业,亦是行业领先的内源性红血球生成素(EPO)制造商,考虑到核心产品TPO在中国的渗透率明显不足,表明仍有较大发展空间。大摩现时维持三生制药的销售预测基本不变,将2024至2026年净利润预测下调14%、14%及13%,每股盈利预测调整为0.9元、1元及1元,目标价从8元下调至7.5元,维持“与大市同步”评级。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340595/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0655},{"period":"1month","weight":0.0109},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.1258},{"period":"1year","weight":-0.2966},{"period":"ytd","weight":-0.2606}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.002754},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.01596},{"month":3,"riseRate":0.777778,"avgChangeRate":0.064891},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.029351},{"month":5,"riseRate":0.75,"avgChangeRate":0.06822},{"month":6,"riseRate":0.75,"avgChangeRate":0.006716},{"month":7,"riseRate":0,"avgChangeRate":-0.086521},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.005754},{"month":9,"riseRate":0.555556,"avgChangeRate":0.015565},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.008535},{"month":11,"riseRate":0.777778,"avgChangeRate":0.073648},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.037241}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}